Apolipoprotein E ϵ4 Count Affects Age at Onset of Alzheimer Disease,but Not Lifetime Susceptibility: The Cache County Study
Abstract
BACKGROUND: The incidence of Alzheimer disease (AD) increases strongly with age, but little is known about the cumulative incidence of AD over a lifetime of 100 years, or its relationship to the polymorphic APOE locus that encodes apolipoprotein E. APOE is a strong genetic risk factor for AD. OBJECTIVES: To estimate the occurrence of AD as a function of age and number of APOE epsilon4 alleles; and to explore evidence for heterogeneity of AD risk related to APOE genotype and to other sources. DESIGN: Nonparametric and parametric survival analyses of AD incidence in prospective longitudinal study. SETTING AND PARTICIPANTS: A total of 3308 elderly residents of Cache County, Utah. MAIN OUTCOME MEASURES: Cumulative incidence of AD; in mixture models assuming susceptible and nonsusceptible individuals, the proportion of individuals not susceptible to AD at any age. RESULTS: Models that assumed a proportion of invulnerable individuals provided strongly improved fit to the data. These models estimated the 100-year lifetime incidence of AD at 72%, implying that 28% of individuals would not develop AD over any reasonable life expectancy. We confirmed the acceleration of AD onset in individuals with 1 or, especially, 2 APOE, epsilon4 alleles but observed no meaningful difference in 100-year lifetime incidence related to number of epsilon4 alleles. CONCLUSIONS: The APOE epsilon4 allele acts as a potent risk factor for AD by accelerating onset. However, the risk of AD appears heterogeneous in ways independent of APOE. Some individuals seem destined to escape AD, even over an extended lifespan. Their relative invulnerability may reflect other genes or environmental factors that can be investigated.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Classifiers using multimodal biological, imaging, and neuropsychological markers can separate AD patients from cognitively normal individuals accurately.
“Multi-modal biological, imaging, and neuropsychological markers have demonstrated promising performance for distinguishing Alzheimer’s disease (AD) patients from cognitively normal elders.”
Not all ε4 carriers develop AD, and not all AD patients are ε4 carriers; the ε2 allele seems to play a protective role.
“However, not all ε4 carriers develop AD, and not all AD patients are ε4 carriers; rather, the ε2 allele seems to play a protective role [45], [46].”
From Atrophy of presubiculum and subiculum is the earliest hippocampal anatomical marker of Alzheimer's disease (2015) · cites this paper as [46]
The citation lists haven’t been fetched yet
References 29 · Cited by 176
- Authors
- Khachaturian, A. S.
- Corresponding author
- Khachaturian, Ara S.
- ORCID
- Khachaturian, Ara S.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2004-05-01
- Volume
- 61
- Issue
- 5
- Pages
- 518
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2011837326
- Cited by
- 176
- References
- 29
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 7 · 2014: 10 · 2013: 15 · 2012: 18
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Utah State University
- University of Washington
- Johns Hopkins University
- National Institutes of Health
- Johns Hopkins Bloomberg School of Public Health
- Geriatric Research Education and Clinical Center
- National Institute on Aging (AG11-380, R01AG011380)
- National Institute of Mental Health (MH-14592, T32MH014592)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, apolipoprotein E, APOE ε4, APOE genotype, age of onset, lifetime incidence, cumulative incidence, genetic risk factors, invulnerability, Cache County, Utah
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Apolipoproteins E, Female, Genotype, Humans, Longitudinal Studies, Male, Prospective Studies, Risk Factors, Utah, Incidence, Survival Analysis, Age of Onset, Genetic Heterogeneity, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review